Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis

Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis

Abstract Background Multiple sclerosis is an inflammatory demyelination process in the central nervous system (CNS) causing neurological disability and poor quality of life. Currently, Thai Food and Drug Administration (FDA)-approved disease-modifying therapy is costly, and most patients with multip...

Full description

Bibliographic Details
Main Authors: Saharat Aungsumart, Saowalak Turongkaravee, Sitaporn Youngkong, Metha Apiwattanakul, Ammarin Thakkinstian, Usa Chaikledkaew
Format: Article
Language:English
Published: BMC 2023-10-01
Series:BMC Health Services Research
Subjects:
Rituximab
Multiple sclerosis
Cost-utility analysis
Online Access:https://doi.org/10.1186/s12913-023-10099-1

Internet

https://doi.org/10.1186/s12913-023-10099-1

Similar Items